Our Mission

To eliminate the threat of recurrent cancer.

Our mission is to extend the lives of people with advanced stage cancer. We hope to fulfill this mission by harnessing innovative science in antibody engineering and the combined knowledge of our team in oncology and drug development. We came together and built Frezent because we envision a future where long-lasting remission is the reality for all cancer patients.

Co-founders

Natasha Shtraizent, PhD

Chief Executive Officer

Lina Freage-Kahn, PhD

Chief Scientific Officer

Our Advisory Board

Zekzer & Associates | Global Source Ventures

Dan Zekzer, MD PhD

Marshall Posner, MD

Icahn School of Medicine at Mount Sinai

Richard MacDonald, PhD

University of Nebraska Medical Center

Jenik Radon, Esq

Radon Law Offices

Avital Weiss, PhD, MBA

Taysha

Edward Greenfield, PhD

Brigham and Women’s Hospital

Dov Tamarkin, PhD

DermAb.io

Efrat Eliyahu, PhD

Icahn School of Medicine at Mount Sinai

Elena Itskovich, PhD

Nest Catalyst

Jerome Zeldis, MD, PhD

Celgene Corporation | Sorrento Therapeutics (formerly)

  • “We want to give cancer survivors the confidence that their cancer won’t return, and to bring them and their families peace of mind.”

    Natasha Shtraizent, PhD, co-founder and CEO of FREZENT